|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Osmani L, Askin F, Gabrielson E and Li QK:
Current WHO guidelines and the critical role of immunohistochemical
markers in the subclassification of non-small cell lung carcinoma
(NSCLC): Moving from targeted therapy to immunotherapy. Semin
Cancer Biol. 52:103–109. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gettinger S, Horn L, Jackman D, Spigel D,
Antonia S, Hellmann M, Powderly J, Heist R, Sequist LV, Smith DC,
et al: Five-year follow-up of nivolumab in previously treated
advanced non-small-cell lung cancer: Results from the CA209-003
study. J Clin Oncol. 36:1675–1684. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kelly K, Crowley J, Bunn PA Jr, Presant
CA, Grevstad PK, Moinpour CM, Ramsey SD, Wozniak AJ, Weiss GR,
Moore DF, et al: Randomized phase III trial of paclitaxel plus
carboplatin versus vinorelbine plus cisplatin in the treatment of
patients with advanced non-small-cell lung cancer: A Southwest
oncology group trial. J Clin Oncol. 19:3210–3218. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology Group, : Comparison of four chemotherapy
regimens for advanced non-small-cell lung cancer. N Engl J Med.
346:92–98. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McNutt M: Cancer immunotherapy. Science.
342:14172013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zago G, Muller M, van den Heuvel M and
Baas P: New targeted treatments for non-small-cell lung cancer-role
of nivolumab. Biologics. 10:103–117. 2016.PubMed/NCBI
|
|
9
|
Camidge DR, Doebele RC and Kerr KM:
Comparing and contrasting predictive biomarkers for immunotherapy
and targeted therapy of NSCLC. Nat Rev Clin Oncol. 16:341–355.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Suresh K, Naidoo J, Lin CT and Danoff S:
Immune checkpoint immunotherapy for non-small cell lung cancer:
Benefits and pulmonary toxicities. Chest. 154:1416–1423. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Santini FC, Rizvi H, Plodkowski AJ, Ni A,
Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF,
Long NM, et al: Safety and efficacy of re-treating with
immunotherapy after immune-related adverse events in patients with
NSCLC. Cancer Immunol Res. 6:1093–1099. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Di Giacomo AM, Danielli R, Guidoboni M,
Calabrò L, Carlucci D, Miracco C, Volterrani L, Mazzei MA, Biagioli
M, Altomonte M and Maio M: Therapeutic efficacy of ipilimumab, an
anti-CTLA-4 monoclonal antibody, in patients with metastatic
melanoma unresponsive to prior systemic treatments: Clinical and
immunological evidence from three patient cases. Cancer Immunol
Immunother. 58:1297–1306. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Champiat S, Dercle L, Ammari S, Massard C,
Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A,
Soria JC and Ferté C: Hyperprogressive disease is a new pattern of
progression in cancer patients treated by anti-PD-1/PD-L1. Clin
Cancer Res. 23:1920–1928. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xia L, Liu Y and Wang Y: PD-1/PD-L1
blockade therapy in advanced non-small-cell lung cancer: Current
status and future directions. Oncologist. 24 (Suppl 1):S31–S41.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang Y: Cancer immunotherapy: Harnessing
the immune system to battle cancer. J Clin Invest. 125:3335–3337.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang W, Liu J, He Y and McLeod HL:
Prospect for immune checkpoint blockade: Dynamic and comprehensive
monitorings pave the way. Pharmacogenomics. 18:1299–1304. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Almand B and Carbone DP: Biological
considerations in lung cancer. Cancer Treat Res. 105:1–30. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Assi HI, Kamphorst AO, Moukalled NM and
Ramalingam SS: Immune checkpoint inhibitors in advanced non-small
cell lung cancer. Cancer. 124:248–261. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen L and Flies DB: Molecular mechanisms
of T cell co-stimulation and co-inhibition. Nat Rev Immunol.
13:227–242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schildberg FA, Klein SR, Freeman GJ and
Sharpe AH: Coinhibitory pathways in the B7-CD28 ligand-receptor
family. Immunity. 44:955–972. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rowshanravan B, Halliday N and Sansom DM:
CTLA-4: A moving target in immunotherapy. Blood. 131:58–67. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arce Vargas F, Furness AJS, Litchfield K,
Joshi K, Rosenthal R, Ghorani E, Solomon I, Lesko MH, Ruef N,
Roddie C, et al: Fc effector function contributes to the activity
of human anti-CTLA-4 antibodies. Cancer Cell. 33:649–663.e4. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Walker LS: Treg and CTLA-4: Two
intertwining pathways to immune tolerance. J Autoimmun. 45:49–57.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Corrales L, Scilla K, Caglevic C, Miller
K, Oliveira J and Rolfo C: Immunotherapy in lung cancer: A new age
in cancer treatment. Adv Exp Med Biol. 995:65–95. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Govindan R, Szczesna A, Ahn MJ, Schneider
CP, Gonzalez Mella PF, Barlesi F, Han B, Ganea DE, Von Pawel J,
Vladimirov V, et al: Phase III trial of ipilimumab combined with
paclitaxel and carboplatin in advanced squamous non-small-cell lung
cancer. J Clin Oncol. 35:3449–3457. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boussiotis VA, Chatterjee P and Li L:
Biochemical signaling of PD-1 on T cells and its functional
implications. Cancer J. 20:265–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang X, Teng F, Kong L and Yu J: PD-L1
expression in human cancers and its association with clinical
outcomes. Onco Targets Ther. 9:5023–5039. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Machicote A, Belén S, Baz P, Billordo LA
and Fainboim L: Human CD8+HLA-DR+ regulatory T cells, similarly to
classical CD4+Foxp3+ cells, suppress immune responses via
PD-1/PD-L1 axis. Front Immunol. 9:27882018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ventriglia J, Paciolla I, Pisano C, Cecere
SC, Di Napoli M, Tambaro R, Califano D, Losito S, Scognamiglio G,
Setola SV, et al: Immunotherapy in ovarian, endometrial and
cervical cancer: State of the art and future perspectives. Cancer
Treat Rev. 59:109–116. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yahata T, Mizoguchi M, Kimura A, Orimo T,
Toujima S, Kuninaka Y, Nosaka M, Ishida Y, Sasaki I, Fukuda-Ohta Y,
et al: Programmed cell death ligand 1 disruption by clustered
regularly interspaced short palindromic repeats/Cas9-genome editing
promotes antitumor immunity and suppresses ovarian cancer
progression. Cancer Sci. 110:1279–1292. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Boussiotis VA: Molecular and biochemical
aspects of the PD-1 checkpoint pathway. N Engl J Med.
375:1767–1778. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gajewski TF, Schreiber H and Fu YX: Innate
and adaptive immune cells in the tumor microenvironment. Nat
Immunol. 14:1014–1022. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Spranger S, Spaapen RM, Zha Y, Williams J,
Meng Y, Ha TT and Gajewski TF: Up-regulation of PD-L1, IDO, and
T(regs) in the melanoma tumor microenvironment is driven by CD8(+)
T cells. Sci Transl Med. 5:200ra1162013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: Atezolizumab versus docetaxel in patients with
previously treated non-small-cell lung cancer (OAK): A phase 3,
open-label, multicentre randomised controlled trial. Lancet.
389:255–265. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Vokes EE, Ready N, Felip E, Horn L, Burgio
MA, Antonia SJ, Arén Frontera O, Gettinger S, Holgado E, Spigel D,
et al: Nivolumab versus docetaxel in previously treated advanced
non-small-cell lung cancer (CheckMate 017 and CheckMate 057):
3-Year update and outcomes in patients with liver metastases. Ann
Oncol. 29:959–965. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Reck M, Rodriguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: Pembrolizumab versus chemotherapy for PD-L1-positive
non-small-cell lung cancer. N Engl J Med. 375:1823–1833. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Nosaki K, Saka H, Hosomi Y, Baas P, de
Castro G Jr, Reck M, Wu YL, Brahmer JR, Felip E, Sawada T, et al:
Safety and efficacy of pembrolizumab monotherapy in elderly
patients with PD-L1-positive advanced non-small-cell lung cancer:
Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042
studies. Lung Cancer. 135:188–195. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lopes G, Wu YL, Kudaba I, Kowalski D, Cho
BC, Bondarenko I, Kubota K, Lubiniecki GM, Zhang J, Kush DA and Mok
T: Pembrolizumab (pembro) versus platinum-based chemotherapy
(chemo) as first-line therapy for advanced/metastatic NSCLC with a
PD-L1 tumor proportion score (TPS) >= 1%: Open-label, phase 3
KEYNOTE-042 study. J Clin Oncol. 36 (18 Suppl):LBA4. 2018.
View Article : Google Scholar
|
|
40
|
Mok TSK, Wu YL, Kudaba I, Kowalsk DM, Cho
BC, Turna HZ, de Castro G Jr, Srimuninnimit V, Laktionov KK,
Bondarenko I, et al: Final analysis of the phase III KEYNOTE-042
study: Pembrolizumab (Pembro) versus platinum-based chemotherapy
(Chemo) as first-line therapy for patients (Pts) with
PD-L1-positive locally advanced/metastatic NSCLC. Ann Oncol. 30
(Suppl 2):ii38–ii68. 2019. View Article : Google Scholar
|
|
41
|
Oezkan F, He K, Owen D, Pietrzak M, Cho
Jh, Kitzler R, Pearson R, Rusch V, Chaft J, Suh R, et al: OA13.07
Neoadjuvant atezolizumab in resectable NSCLC patients:
Immunophenotyping results from the interim analysis of the
multicenter trial LCMC3. J Thorac Oncol. 14 (10 Suppl):S242–S243.
2019. View Article : Google Scholar
|
|
42
|
Gandhi L, Rodriguez-Abreu D, Gadgeel S,
Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ,
Powell SF, et al: Pembrolizumab plus chemotherapy in metastatic
non-small-cell lung cancer. N Engl J Med. 378:2078–2092. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
West H, McCleod M, Hussein M, Morabito A,
Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, et
al: Atezolizumab in combination with carboplatin plus
nab-paclitaxel chemotherapy compared with chemotherapy alone as
first-line treatment for metastatic non-squamous non-small-cell
lung cancer (IMpower130): A multicentre, randomised, open-label,
phase 3 trial. Lancet Oncol. 20:924–937. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, et
al: Overall survival with durvalumab after chemoradiotherapy in
stage III NSCLC. N Engl J Med. 379:2342–2350. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Socinski MA, Jotte RM, Cappuzzo F, Orlandi
F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D,
Thomas CA, Barlesi F, et al: Atezolizumab for first-line treatment
of metastatic nonsquamous NSCLC. N Engl J Med. 378:2288–2301. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Buchbinder EI and Desai A: CTLA-4 and PD-1
pathways: Similarities, differences, and implications of their
inhibition. Am J Clin Oncol. 39:98–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wei SC, Levine JH, Cogdill AP, Zhao Y,
Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'er D and
Allison JP: Distinct cellular mechanisms underlie anti-CTLA-4 and
anti-PD-1 checkpoint blockade. Cell. 170:1120–1133.e17. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Curran MA, Montalvo W, Yagita H and
Allison JP: PD-1 and CTLA-4 combination blockade expands
infiltrating T cells and reduces regulatory T and myeloid cells
within B16 melanoma tumors. Proc Natl Acad Sci USA. 107:4275–4280.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Das R, Verma R, Sznol M, Boddupalli CS,
Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R,
Dhodapkar MV and Dhodapkar KM: Combination therapy with anti-CTLA-4
and anti-PD-1 leads to distinct immunologic changes in vivo. J
Immunol. 194:950–959. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Reck M, Schenker M, Lee KH, Provencio M,
Nishio M, Lesniewski-Kmak K, Sangha R, Ahmed S, Raimbourg J, Feeney
K, et al: Nivolumab plus ipilimumab versus chemotherapy as
first-line treatment in advanced non-small-cell lung cancer with
high tumour mutational burden: Patient-reported outcomes results
from the randomised, open-label, phase III CheckMate 227 trial. Eur
J Cancer. 116:137–147. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Brahmer J, Reckamp KL, Baas P, Crinò L,
Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE,
Holgado E, et al: Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. New Engl J Med.
373:123–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Fehrenbacher L, Spira A, Ballinger M,
Kowanetz M, Vansteenkiste J, Mazieres J, Park K, Smith D,
Artal-Cortes A, Lewanski C, et al: Atezolizumab versus docetaxel
for patients with previously treated non-small-cell lung cancer
(POPLAR): A multicentre, open-label, phase 2 randomised controlled
trial. Lancet. 387:1837–1846. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y,
Lin D, Gao Q, Zhou H, Liao W and Yao H: Association of survival and
immune-related biomarkers with immunotherapy in patients with
non-small cell lung cancer: A meta-analysis and individual
patient-level analysis. JAMA Netw Open. 2:e1968792019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chan TA, Yarchoan M, Jaffee E, Swanton C,
Quezada SA, Stenzinger A and Peters S: Development of tumor
mutation burden as an immunotherapy biomarker: Utility for the
oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Salmaninejad A, Valilou SF, Shabgah AG,
Aslani S, Alimardani M, Pasdar A and Sahebkar A: PD-1/PD-L1
pathway: Basic biology and role in cancer immunotherapy. J Cell
Physiol. 234:16824–16837. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Patel SP and Kurzrock R: PD-L1 expression
as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther.
14:847–856. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Gibney GT, Weiner LM and Atkins MB:
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Lancet Oncol. 17:e542–e551. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Carbone DP, Reck M, Paz-Ares L, Creelan B,
Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F,
et al: First-line nivolumab in stage IV or recurrent non-small-cell
lung cancer. New Engl J Med. 376:2415–2426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Garon EB, Rizvi NA, Hui RN, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al: Pembrolizumab for the treatment of non-small-cell lung
cancer. New Engl J Med. 372:2018–2028. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Fumet JD, Truntzer C, Yarchoan M and
Ghiringhelli F: Tumour mutational burden as a biomarker for
immunotherapy: Current data and emerging concepts. Eur J Cancer.
131:40–50. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Johnson DB, Frampton GM, Rioth MJ, Yusko
E, Xu Y, Guo X, Ennis RC, Fabrizio D, Chalmers ZR, Greenbowe J, et
al: Targeted next generation sequencing identifies markers of
response to PD-1 blockade. Cancer Immunol Res. 4:959–967. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yarchoan M, Hopkins A and Jaffee EM: Tumor
mutational burden and response rate to PD-1 inhibition. N Engl J
Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hellmann MD, Ciuleanu TE, Pluzanski A, Lee
JS, Otterson GA, Audigier-Valette C, Minenza E, Linardou H, Burgers
S, Salman P, et al: Nivolumab plus ipilimumab in lung cancer with a
high tumor mutational burden. N Engl J Med. 378:2093–2104. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Bylicki O, Barazzutti H, Paleiron N,
Margery J, Assié JB and Chouaid C: First-line treatment of
non-small-cell lung cancer (NSCLC) with immune checkpoint
inhibitors. BioDrugs. 33:159–171. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Rizvi H, Sanchez-Vega F, La K, Chatila W,
Jonsson P, Halpenny D, Plodkowski A, Long N, Sauter JL, Rekhtman N,
et al: Molecular determinants of response to anti-programmed cell
death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in
patients with non-small-cell lung cancer profiled with targeted
next-generation sequencing. J Clin Oncol. 36:633–641. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zeng DQ, Yu YF, Ou QY, Li XY, Zhong RZ,
Xie CM and Hu QG: Prognostic and predictive value of
tumor-infiltrating lymphocytes for clinical therapeutic research in
patients with non-small cell lung cancer. Oncotarget.
7:13765–13781. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Geng Y, Shao Y, He W, Hu W, Xu Y, Chen J,
Wu C and Jiang J: prognostic role of tumor-infiltrating lymphocytes
in lung cancer: A meta-analysis. Cell Physiol Biochem.
37:1560–1571. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Dong ZY, Wu SP, Liao RQ, Huang SM and Wu
YL: Potential biomarker for checkpoint blockade immunotherapy and
treatment strategy. Tumour Biol. 37:4251–4261. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Tumeh PC, Harview CL, Yearley JH, Shintaku
IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu
V, et al: PD-1 blockade induces responses by inhibiting adaptive
immune resistance. Nature. 515:568–571. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Sun R, Limkin EJ, Vakalopoulou M, Dercle
L, Champiat S, Han SR, Verlingue L, Brandao D, Lancia A, Ammari S,
et al: A radiomics approach to assess tumour-infiltrating CD8 cells
and response to anti-PD-1 or anti-PD-L1 immunotherapy: An imaging
biomarker, retrospective multicohort study. Lancet Oncol.
19:1180–1191. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Teng MW, Ngiow SF, Ribas A and Smyth MJ:
Classifying cancers based on T-cell infiltration and PD-L1. Cancer
Res. 75:2139–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Tokito T, Azuma K, Kawahara A, Ishii H,
Yamada K, Matsuo N, Kinoshita T, Mizukami N, Ono H, Kage M and
Hoshino T: Predictive relevance of PD-L1 expression combined with
CD8+ TIL density in stage III non-small cell lung cancer patients
receiving concurrent chemoradiotherapy. Eur J Cancer. 55:7–14.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Baretti M and Le DT: DNA mismatch repair
in cancer. Pharmacol Ther. 189:45–62. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Nebot-Bral L, Coutzac C, Kannouche PL and
Chaput N: Why is immunotherapy effective (or not) in patients with
MSI/MMRD tumors? Bull Cancer. 106:105–113. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Quiroga D, Lyerly HK and Morse MA:
Deficient mismatch repair and the role of immunotherapy in
metastatic colorectal cancer. Curr Treat Options Oncol. 17:412016.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Le DT, Kim TW, Van Cutsem E, Geva R, Jäger
D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, et al: Phase II
open-label study of pembrolizumab in treatment-refractory,
microsatellite instability-high/mismatch repair-deficient
metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 38:11–19.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Faivre JC, Adam V, Block V, Metzger M,
Salleron J and Dauchy S: Clinical practice guidelines of the French
association for supportive care in cancer and the French society
for psycho-oncology: Refusal of treatment by adults afflicted with
cancer. Support Care Cancer. 25:3425–3435. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Morse MA, Overman MJ, Hartman L, Khoukaz
T, Brutcher E, Lenz HJ, Atasoy A, Shangguan T, Zhao H and El-Rayes
B: Safety of nivolumab plus low-dose ipilimumab in previously
treated microsatellite instability-high/mismatch repair-deficient
metastatic colorectal cancer. Oncologist. 24:1453–1461. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wang Z, Zhao J, Wang G, Zhang F, Zhang Z,
Zhang F, Zhang Y, Dong H, Zhao X, Duan J, et al: Comutations in DNA
damage response pathways serve as potential biomarkers for immune
checkpoint blockade. Cancer Res. 78:6486–6496. 2018.PubMed/NCBI
|
|
82
|
Teo MY, Seier K, Ostrovnaya I, Regazzi AM,
Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, et
al: Alterations in DNA damage response and repair genes as
potential marker of clinical benefit from PD-1/PD-L1 blockade in
advanced urothelial cancers. J Clin Oncol. 36:1685–1694. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Rodenhuis S, van de Wetering ML, Mooi WJ,
Evers SG, van Zandwijk N and Bos JL: Mutational activation of the
K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of
the lung. N Engl J Med. 317:929–935. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Slebos RJ, Kibbelaar RE, Dalesio O,
Kooistra A, Stam J, Meijer CJ, Wagenaar SS, Vanderschueren RG, van
Zandwijk N, Mooi WJ, et al: K-ras oncogene activation as a
prognostic marker in adenocarcinoma of the lung. N Engl J Med.
323:561–565. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ji M, Liu Y, Li Q, Li X, Ning Z, Zhao W,
Shi H, Jiang J and Wu C: PD-1/PD-L1 expression in non-small-cell
lung cancer and its correlation with EGFR/KRAS mutations. Cancer
Biol Ther. 17:407–413. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Calles A, Liao X, Sholl LM, Rodig SJ,
Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, et
al: Expression of PD-1 and Its ligands, PD-L1 and PD-L2, in smokers
and never smokers with KRAS-mutant lung cancer. J Thorac Oncol.
10:1726–1735. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Peters S, Gettinger S, Johnson ML, Jänne
PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE,
Carcereny Costa E, et al: Phase II trial of atezolizumab as
first-line or subsequent therapy for patients with programmed
death-ligand 1-selected advanced non-small-cell lung cancer
(BIRCH). J Clin Oncol. 35:2781–2789. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kato S, Han SY, Liu W, Otsuka K, Shibata
H, Kanamaru R and Ishioka C: Understanding the function-structure
and function-mutation relationships of p53 tumor suppressor protein
by high-resolution missense mutation analysis. Proc Natl Acad Sci
USA. 100:8424–8429. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z,
Liu SY, Tu HY, Chen HJ, Sun YL, Zhou Q, et al: Potential predictive
value of TP53 and KRAS mutation status for response to PD-1
blockade immunotherapy in lung adenocarcinoma. Clin Cancer Res.
23:3012–3024. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Chabanon RM, Pedrero M, Lefebvre C,
Marabelle A, Soria JC and Postel-Vinay S: Mutational landscape and
sensitivity to immune checkpoint blockers. Clin Cancer Res.
22:4309–4321. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Strickland KC, Howitt BE, Shukla SA, Rodig
S, Ritterhouse LL, Liu JF, Garber JE, Chowdhury D, Wu CJ, D'Andrea
AD, et al: Association and prognostic significance of
BRCA1/2-mutation status with neoantigen load, number of
tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high
grade serous ovarian cancer. Oncotarget. 7:13587–13598. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Jacome AA and Eng C: Role of immune
checkpoint inhibitors in the treatment of colorectal cancer: Focus
on nivolumab. Expert Opin Biol Ther. 19:1247–1263. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Song Z, Cheng G, Xu C, Wang W, Shao Y and
Zhang Y: Clinicopathological characteristics of POLE mutation in
patients with non-small-cell lung cancer. Lung Cancer. 118:57–61.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Mehnert JM, Panda A, Zhong H, Hirshfield
K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L,
Kaufman HL, et al: Immune activation and response to pembrolizumab
in POLE-mutant endometrial cancer. J Clin Invest. 126:2334–2340.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Sharma P, Hu-Lieskovan S, Wargo JA and
Ribas A: Primary, adaptive, and acquired resistance to cancer
immunotherapy. Cell. 168:707–723. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Syn NL, Teng MWL, Mok TSK and Soo RA:
De-novo and acquired resistance to immune checkpoint targeting.
Lancet Oncol. 18:e731–e741. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Knutson KL and Disis ML: Tumor
antigen-specific T helper cells in cancer immunity and
immunotherapy. Cancer Immunol Immunother. 54:721–728. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Cha JH, Chan LC, Li CW, Hsu JL and Hung
MC: Mechanisms controlling PD-L1 expression in cancer. Mol Cell.
76:359–370. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Lin H, Wei S, Hurt EM, Green MD, Zhao L,
Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, et al: Host
expression of PD-L1 determines efficacy of PD-L1 pathway
blockade-mediated tumor regression. J Clin Invest. 128:17082018.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Gainor JF, Shaw AT, Sequist LV, Fu X,
Azzoli CG, Piotrowska Z, Huynh TG, Zhao L, Fulton L, Schultz KR, et
al: EGFR mutations and ALK rearrangements are associated with low
response rates to PD-1 pathway blockade in non-small cell lung
cancer: A retrospective analysis. Clin Cancer Res. 22:4585–4593.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Hastings K, Yu HA, Wei W, Sanchez-Vega F,
DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, et al:
EGFR mutation subtypes and response to immune checkpoint blockade
treatment in non-small-cell lung cancer. Ann Oncol. 30:1311–1320.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Garassino MC, Gelibter AJ, Grossi F,
Chiari R, Soto Parra H, Cascinu S, Cognetti F, Turci D, Blasi L,
Bengala C, et al: Italian nivolumab expanded access program in
nonsquamous non-small cell lung cancer patients: Results in
never-smokers and EGFR-mutant patients. J Thorac Oncol.
13:1146–1155. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Garassino MC, Cho BC, Kim JH, Mazières J,
Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J,
Chouaid C, et al: Durvalumab as third-line or later treatment for
advanced non-small-cell lung cancer (ATLANTIC): An open-label,
single-arm, phase 2 study. Lancet Oncol. 19:521–536. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Su S, Dong ZY, Xie Z, Yan LX, Li YF, Su J,
Liu SY, Yin K, Chen RL, Huang SM, et al: Strong programmed death
ligand 1 expression predicts poor response and de novo resistance
to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR
mutation. J Thorac Oncol. 13:1668–1675. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Briscoe J, Guschin D, Rogers NC, Watling
D, Müller M, Horn F, Heinrich P, Stark GR and Kerr IM: JAKs, STATs
and signal transduction in response to the interferons and other
cytokines. Philos Trans R Soc Lond B Biol Sci. 351:167–171. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Shin DS, Zaretsky JM, Escuin-Ordinas H,
Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, Grasso CS, Hugo W,
Sandoval S, Torrejon DY, et al: Primary resistance to PD-1 blockade
mediated by JAK1/2 mutations. Cancer Discov. 7:188–201. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Garcia-Diaz A, Shin DS, Moreno BH, Saco J,
Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X,
et al: Interferon receptor signaling pathways regulating PD-L1 and
PD-L2 expression. Cell Rep. 29:37662019. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Massacesi C, di Tomaso E, Fretault N and
Hirawat S: Challenges in the clinical development of PI3K
inhibitors. Ann N Y Acad Sci. 1280:19–23. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Mendes RD, Canté-Barrett K, Pieters R and
Meijerink JP: The relevance of PTEN-AKT in relation to
NOTCH1-directed treatment strategies in T-cell acute lymphoblastic
leukemia. Haematologica. 101:1010–1017. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Peng W, Chen JQ, Liu C, Malu S, Creasy C,
Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al: Loss of
PTEN promotes resistance to T cell-mediated immunotherapy. Cancer
Discov. 6:202–216. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Roh MR, Gupta S, Park KH, Chung KY, Lauss
M, Flaherty KT, Jönsson G, Rha SY and Tsao H: Promoter methylation
of PTEN Is a significant prognostic factor in melanoma survival. J
Invest Dermatol. 136:1002–1011. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Biton J, Mansuet-Lupo A, Pécuchet N,
Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser
F, Leroy K, Goc J, et al: TP53, STK11, and EGFR mutations predict
tumor immune profile and the response to Anti-PD-1 in lung
adenocarcinoma. Clin Cancer Res. 24:5710–5723. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Skoulidis F, Goldberg ME, Greenawalt DM,
Hellmann MD, Awad MM, Gainor JF, Schrock AB, Hartmaier RJ, Trabucco
SE, Gay L, et al: STK11/LKB1 mutations and PD-1 inhibitor
resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov.
8:822–835. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Jamme P, Fernandes M, Copin MC,
Descarpentries C, Escande F, Morabito A, Grégoire V, Jamme M,
Baldacci S, Tulasne D, et al: Alterations in the PI3K pathway drive
resistance to MET inhibitors in NSCLC harboring MET exon 14
skipping mutations. J Thorac Oncol. 15:741–751. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Saigi M, Alburquerque-Bejar JJ and
Sanchez-Cespedes M: Determinants of immunological evasion and
immunocheckpoint inhibition response in non-small cell lung cancer:
The genetic front. Oncogene. 38:5921–5932. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Zaretsky JM, Garcia-Diaz A, Shin DS,
Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY,
Abril-Rodriguez G, Sandoval S, Barthly L, et al: Mutations
associated with acquired resistance to PD-1 blockade in melanoma. N
Engl J Med. 375:819–829. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Gettinger S, Choi J, Hastings K, Truini A,
Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, et al:
Impaired HLA class I antigen processing and presentation as a
mechanism of acquired resistance to immune checkpoint inhibitors in
lung cancer. Cancer Discov. 7:1420–1435. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
S Saâda-Bouzid E, Defaucheux C,
Karabajakian A, Coloma VP, Servois V, Paoletti X, Even C, Fayette
J, Guigay J, Loirat D, et al: Hyperprogression during
anti-PD-1/PD-L1 therapy in patients with recurrent and/or
metastatic head and neck squamous cell carcinoma. Ann Oncol.
28:1605–1611. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Fuentes-Antrás J, Provencio M and
Diaz-Rubio E: Hyperprogression as a distinct outcome after
immunotherapy. Cancer Treat Rev. 70:16–21. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Kato S, Goodman A, Walavalkar V,
Barkauskas DA, Sharabi A and Kurzrock R: Hyperprogressors after
immunotherapy: Analysis of genomic alterations associated with
accelerated growth rate. Clin Cancer Res. 23:4242–4250. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Mazieres J, Drilon A, Lusque A, Mhanna L,
Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, et
al: Immune checkpoint inhibitors for patients with advanced lung
cancer and oncogenic driver alterations: Results from the
IMMUNOTARGET registry. Ann Oncol. 30:1321–1328. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Ferrara R, Mezquita L, Texier M, Lahmar J,
Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau
S, Le Moulec S, et al: Hyperprogressive disease in patients with
advanced non-small cell lung cancer treated with PD-1/PD-L1
inhibitors or with single-agent chemotherapy. JAMA Oncol.
4:1543–1552. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Kim CG, Kim KH, Pyo KH, Xin CF, Hong MH,
Ahn BC, Kim Y, Choi SJ, Yoon HI, Lee JG, et al: Hyperprogressive
disease during PD-1/PD-L1 blockade in patients with non-small-cell
lung cancer. Ann Oncol. 30:1104–1113. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Champiat S, Ferrara R, Massard C, Besse B,
Marabelle A, Soria JC and Ferté C: Hyperprogressive disease:
Recognizing a novel pattern to improve patient management. Nat Rev
Clin Oncol. 15:748–762. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Oliner JD, Saiki AY and Caenepeel S: The
role of MDM2 amplification and overexpression in tumorigenesis.
Cold Spring Harb Perspect Med. 6:a0263362016. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Kato S, Ross JS, Gay L, Dayyani F, Roszik
J, Subbiah V and Kurzrock R: Analysis of MDM2 amplification:
Next-generation sequencing of patients with diverse malignancies.
JCO Precis Oncol 2018. 10.1200/PO.17.00235. 2018. View Article : Google Scholar
|
|
128
|
Giusti R, Mazzotta M, Filetti M, Marinelli
D, Di Napoli A, Scarpino S, Scafetta G, Mei M, Vecchione A, Ruco L
and Marchetti P: CDKN2A/B gene loss and MDM2 alteration as a
potential molecular signature for hyperprogressive disease in
advanced NSCLC: A next-generation-sequencing approach. J Clin
Oncol. 37 (15 Suppl):e20628. 2019. View Article : Google Scholar
|
|
129
|
Auslander N, Zhang G, Lee JS, Frederick
DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, et al:
Robust prediction of response to immune checkpoint blockade therapy
in metastatic melanoma. Nat Med. 24:1545–1549. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Mezquita L, Auclin E, Ferrara R, Charrier
M, Remon J, Planchard D, Ponce S, Ares LP, Leroy L,
Audigier-Valette C, et al: Association of the lung immune
prognostic index with immune checkpoint inhibitor outcomes in
patients with advanced non-small cell lung cancer. JAMA Oncol.
4:351–357. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Harders SW, Balyasnikowa S and Fischer BM:
Functional imaging in lung cancer. Clin Physiol Funct Imaging.
34:340–355. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Rossi S, Castello A, Toschi L and Lopci E:
Immunotherapy in non-small-cell lung cancer: Potential predictors
of response and new strategies to assess activity. Immunotherapy.
10:797–805. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Vrankar M and Unk M: Immune RECIST
criteria and symptomatic pseudoprogression in non-small cell lung
cancer patients treated with immunotherapy. Radiol Oncol.
52:365–369. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Andrews MC and Wargo JA: Cancer evolution
during immunotherapy. Cell. 171:740–742. 2017. View Article : Google Scholar : PubMed/NCBI
|
